Mark Noar, MD (Chairman, CEO and Director): joined the Company’s board in 2001. Dr.
Noar is a private practice gastroenterologist, with a large clinic in Towson, MD. He has conducted a number of clinical research projects, including the ability of EGG to screen and predict success with surgical intervention for GERD patients. He has published extensively and is an acknowledged expert in reimbursement matters for private practice. He is an advisor to the pharmaceutical and medical device industries, with a successful history of technology introduction and evaluation. Dr. Noar is a graduate of the Universidad Central Del Este Dominican Republic School of Medicine and also has an MPH from the Tulane University. Since joining the company he has overseen the development and patent of the newer version of the EGG, integrating computer-based interpretation and diagnostics into the field and the latest open architecture Research focused EGG, selected as the exclusive EGG used by the NIH in their sponsored research.
Bernie DiDario (Director and Co-Founder): prior to joining 3CPM® Company, was the President and CEO of Maven Labs, Inc., a company specializing in the development of noninvasive devices for treating pain and discomfort.
From 1984 to 1990 he was the President of Industrial Fermentation Genetics, a biotech Company which manufactured and sold specialty proteins derived from genetic engineering. The Company was acquired in 1990. From 1982 to 1984 he was the President of California Integrated Diagnostics, a manufacturer of kits for the detection of sexually transmitted diseases. The Company was acquired in 1984 by a larger competitor. He was also a senior consultant with Arthur D. Little, Inc. and was involved with strategic and marketing assignments with numerous companies in the medical area. He has an undergraduate degree in management from Boston University (1976) and graduate degree in Health Policy and Management from Harvard University (1981). Mr. DiDario currently serves on the Board of three companies with a technology focus and products for the financial services and RFID/GPS asset tracking markets.
Wendell W. Jones II (Director): Since 2008 Mr. Jones is “The Serial CFO” where he provides interim and consulting CFO services to a number of embryonic Companies in Silicon Valley including a laser manufacturer, a medical device company, and several small businesses which require finance and/or accounting advice. From 2004 through 2008, he was a Director for the CPA firm Louie and Wong. From 1997 through 2004, he was the CFO of 3CPM through 2004. Prior to that he was the CFO for Maven Labs, Inc. from 1992 to 1997, where he was responsible for finance, accounting, investor relations, treasury and information systems functions. From 1990 to 1992, he was a consultant to the Chairman of Network Solutions, Inc., a Company that engaged in the exclusive registration of Internet addresses. From 1980 to 1983, he was as senior consultant for Arthur D. Little, Inc. where he focused on technology companies. From 1983 to 1990 he was the CFO of Industrial Fermentation Genetics, Inc. (which successfully completed IPO’s in the US and UK) as well as a director and cofounder. In 1976, he graduated from George Washington University with a degree in accounting. He received a Masters in Business Administration from Washington University’s Olin School of Business in 1978. Mr. Jones is also Board Chair for Main Street Launch.
Mr. Carlos Babini Chief Commercialization Officer and Senior Vice President of SurgiQuest, Inc. a private, start-up medical device company where he helped build revenue to 50 Million Dollars prior to its acquisition earlier part of 2016 by CONMED Corporation (CNMD) for 265 Million US Dollars.Carlos Babini, joined SurgiQuest in 2008, as an accomplished senior executive with more than 25 years of key leadership experience in sales, marketing, strategic development and commercialization initiatives in highly competitive sectors of both the capital and non-capital medical device industry.
Prior to joining SurgiQuest, Mr. Babini served as the Executive Vice President and Chief Sales & Marketing Officer for both Vision Sciences and Curon, both public medical device companies. During his 20 year career at U.S. Surgical Corporation he helped build sales revenue to 1.3 Billion US Dollars prior to the sale of USSC to Tyco Healthcare, later known as Covidien (now Medtronic) for 3.9 Billion US Dollars. Mr. Babini is globally recognized for building high performance, extremely disciplined, customer focused world-class teams and for facilitating organizational high standards of excellence.